Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mark Holoboski is active.

Publication


Featured researches published by Mark Holoboski.


Pharmaceutical patent analyst | 2004

Prostaglandin ep4 antagonists

Larry A. Wheeler; Michael E. Garst; Yanbin Liang; David F. Woodward; Achim H.-P. Krauss; Robert M. Burk; Yariv Donde; Mark Holoboski; David W. Old; June Chen

Prostaglandin antagonists, with their pharmacological effects, are well-known drugs capable of treating widely diffused illnesses, including pain and inflammation disorders. In recent years, a major research focus has been devoted to the identification of agents able to selectively antagonize each receptor with which prostaglandins interact. This review attempts to give a broad overview of molecules capable of selectively blocking the prostaglandin PGE2 EP4 receptor. Further therapeutic applications and uses have also been disccussed, including the first drug candidate to have reached clinical trials within the last few years.


Archive | 2002

ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists

Robert M. Burk; Mark Holoboski; Mari F. Posner


Archive | 2002

3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure

Robert M. Burk; Mark Holoboski; Mari F. Posner


Archive | 2005

Therapeutic and delivery methods of prostaglandin ep4 agonists

Wha-Bin Im; Robert M. Burk; Mark Holoboski


Archive | 2003

EP4 agonists as agents for lowering intraocular pressure

David F. Woodward; Achim H.-P. Krauss; Robert M. Burk; Mark Holoboski; Mari F. Posner


Archive | 2009

Combination therapy for glaucoma

Scott M. Whitcup; Robert M. Burk; David W. Old; Yariv Donde; Wha-Bin Im; Mark Holoboski


Archive | 2008

Therapeutic substituted cyclopentanes for reducing intraocular pressure

David W. Old; Mark Holoboski; Mari F. Posner


Archive | 2001

Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents

Robert M. Burk; Mark Holoboski; Mari F. Posner


Archive | 2007

PROSTAGLANDIN EP4 AGONISTS

Wha Bin Im; Robert M. Burk; Mark Holoboski


Archive | 2005

Combination therapy for glaucoma treatment

Robert M. Burk; Mark Holoboski; Scott M. Whitcup; Wha-Bin Im

Collaboration


Dive into the Mark Holoboski's collaboration.

Researchain Logo
Decentralizing Knowledge